Recent partnership deals for the current, but less effective drugs were valued at least 500m per drug / vaxx.
IMU got 6 in development, therefore $ 3b very likely according to the recent comments by management. Let's get confirmation from the "every minute due" ph 1 b trial and the sp will be way above 10c.
Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing PD-1, HER-1, HER-2, HER-3, VEGF, IGF-1R cancer immunotherapies. Our mission is to build a pipeline of B-cell peptide cancer vaccines and therapeutics.
View MD/CEO Leslie Chong being interviewed by Commsec's Tom Piotrowski 13 June 2018 (click here). View 2017 Imugene Immuno-Oncology Expert Briefing featuring Dr Axel Hoos, Prof Dr Christoph Zielinski and Prof Dr Ursula Wiedermann (click here)
Our lead product is
HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®. Imugene is also developing a B cell vaccine, KEY-Vaxx, targeting PD-1 and specifically the same PD-1 binding region of Keytruda®.
We also added by way of an
announcement on 7 June 2018, an exclusive, world-wide licence to the entire body of cancer vaccine work and intellectual property developed by Professor Pravin T. P. Kaumaya of The Ohio State University Wexner Medical Center and The Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and The Mayo Clinic. Included in the pipeline is a PD-1 targeting cancer vaccine, KEY-Vaxx, that has shown robust inhibition of tumour growth in validated pre-clinical animal models.
Click here to view latest Imugene Fact Sheet
Click here to view video that introduces HER-Vaxx and explains how it works
Click here to view Imugene's current share price
Click here to view Leslie Chong interview with Medicalresearch.com "Imugene Building Pipeline of B Cell Peptide Cancer Vaccines".
Click here to read "What's Hot & What's Not in Immuno-Oncology Licensing. Dr Axel Hoos is interviewed as part of an expert panel.
HER-Vaxx has successfully completed a Phase 1 study in breast cancer and has commenced in 2017 a Phase 1b/2 study in HER2+ gastric cancer. Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.
HER-Vaxx has shown success in stimulating the production of lifesaving HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. Its further development is directed towards providing a natural, potentially more potent alternative to Roche’s popular injectable antibody, Herceptin®, which have become one of the world’s bestselling cancer drugs with annual sales in excess of $US6.7 billion (Roche Investor Update 30/1/17).
Imugene in partnership with the Medical University of Vienna is working to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create game-changing B Cell peptide vaccines that would replace or augment conventional monoclonal antibody therapies.
Imugene is also building a pipeline of small molecule immuno-oncology drugs. Arginine is a critical amino acid for the health of cancer fighting T-cells and depletion of it limits the effectiveness of T-cells to fight tumours. We are leveraging our core expertise in tumor biology and medicinal chemistry to develop small molecule selective arginine modulators.
Imugene’s corporate headquarters are located in Melbourne, Australia with most of the scientific team in Vienna, Austria.
(20min delay)